Search

Your search keyword '"Rosanne Superstein"' showing total 13 results
Start Over Author "Rosanne Superstein" Search Limiters Available in Library Collection
13 results on '"Rosanne Superstein"'

1. Retinoblastoma with and without Extraocular Tumor Extension

Author

Swathi Kaliki, MD, Vijitha S. Vempuluru, MD, Ido Didi Fabian, MD, Elhassan Abdallah, MD, Shehu U. Abdullahi, MD, Rula A. Abdulqader, MD, Aminatu A. Abdulrahaman, MD, Sherif Abouelnaga, MD, Dupe S. Ademola-Popoola, FMCOph, FWACS, Adedayo Adio, FWACS, Mahmoud A. Afifi, MD, Armin R. Afshar, MD, Priyanka Aggarwal, MD, Ada E. Aghaji, FMCOph MSc, Alia Ahmad, MRCPCH UK, Marliyanti N.R. Akib, MD, Adeseye M. Akinsete, MBBS, Lamis Al Harby, MD, Saleh A. Al Mesfer, MD, Mouroge H. Al Ani, MD, Silvia Alarcón Portabella, MD, Safaa A.F. Al-Badri, MD, Ana Patricia A. Alcasabas, MD, Saad A. Al-Dahmash, MD, Amanda Alejos, MD, Ernesto Alemany-Rubio, MD, Amadou I. Alfa Bio, MD, Yvania Alfonso Carreras, MD, Christiane E. Al-Haddad, MD, Hamoud H.Y. Al-Hussaini, MD, MSc, Amany M. Ali, MD, Donjeta B. Alia, MD, Mazin F. Al-Jadiry, MD, Usama Al-Jumaly, MD, Hind M. Alkatan, MD, Charlotta All-Eriksson, MD, PhD, Ali A.R.M. Al-Mafrachi, FIBMS, Argentino A. Almeida, MD, Khalifa M. Alsawidi, MD, Athar A.S.M. Al-Shaheen, MD, Entissar H. Al-Shammary, MD, Doreen Amankwaa-Frempong, MBChB, Primawita O. Amiruddin, MD, Inggar Armytasari, MD, Nicholas J. Astbury, FRCS, FRCOphth, Hatice T. Atalay, MD, Eda Ataseven, MD, La-ongsri Atchaneeyasakul, MD, Rose Atsiaya, OCO, Rudolf Autrata, MD, PhD, Julia Balaguer, MD, PhD, Ruhengiz Balayeva, PhD, Honorio Barranco, MD, PhD, Paulina Bartoszek, MD, Katarina Bartuma, MD, PhD, Covadonga Bascaran, MD, MSc, Nikolaos E. Bechrakis, MD, Maja Beck Popovic, MD, Ainura S. Begimkulova, MD, Sarra Benmiloud, MD, Rokia C. Berete, MD, PhD, Jesse L. Berry, MD, Anirban Bhaduri, MD, Sunil Bhat, MBBS, MD, Arpita Bhattacharyya, MD, Eva M. Biewald, MD, Elaine Binkley, MD, Sharon Blum, MD, Nadia Bobrova, MD, H. Culver Boldt, MD, Maria Teresa B.C. Bonanomi, MD, PhD, Gabrielle C. Bouda, MD, Hédi Bouguila, MD, PhD, Rachel C. Brennan, MD, Bénédicte G. Brichard, MD, PhD, Jassada Buaboonnam, MD, Aléine Budiongo, MD, Matthew Burton, FRCOphth, Patricia Calderón-Sotelo, MD, Doris A. Calle Jara, MD, Jayne E. Camuglia, FRANZCO, Miriam R. Cano, MD, MSc, Michael Capra, FRCPI, Shani Caspi, MD, Nathalie Cassoux, MD, PhD, Guilherme Castela, MD, Luis Castillo, MD, Jaume Català-Mora, MD, PhD, Isabel Caviedes, MD, Arthika Chandramohan, MD, Guillermo L. Chantada, MD, PhD, Shabana Chaudhry, MD, Bhavna Chawla, MD, Wensi Chen, MD, Faraja S. Chiwanga, MSc, Tsengelmaa Chuluunbat, MD, PhD, Krzysztof Cieslik, MD, Antony Clark, FRANZCO, Ruellyn L. Cockcroft, MB ChB , M Med Paed, Codruta Comsa, MD, Maria G. Correa Llano, MD, Timothy W. Corson, PhD, Line Couitchere, MD, Kristin E. Cowan-Lyn, MD, MBBS, Monika Csóka, MD, PhD, Wantanee Dangboon, MD, Anirban Das, MD, Pranab Das, MD, Sima Das, MS, Jacquelyn M. Davanzo, BSN, BSPH, Alan Davidson, MBChB, MPhil, Sonia De Francesco, MD, Patrick De Potter, MD, PhD, Karina Q. Delgado, MD, PhD, Hakan Demirci, MD, Laurence Desjardins, MD, Rosdali Y. Diaz Coronado, MD, Helen Dimaras, PhD, Andrew J. Dodgshun, M Phil, Carla R. Donato Macedo, MD, Monica D. Dragomir, MD, PhD, Yi Du, MD, Magritha Du Bruyn, MD, Johannes P. Du Plessis, MMed (Paed), Gagan Dudeja, MBBS, MS, Katrin Eerme, MD, I Wayan Eka Sutyawan, MD, Asmaa El Kettani, MD, Amal M. Elbahi, MD, James E. Elder, MBBS, Alaa M. Elhaddad, MD, PhD, Moawia M.A. Elhassan, MD, Mahmoud M. Elzembely, MD, Connor Ericksen, MD, Vera A. Essuman, FWACS, Ted Grimbert A. Evina, MD, Ifeoma R. Ezegwui, FMCOph, FWACS, FAEH, Zehra Fadoo, MBBS, Adriana C. Fandiño, MD, Mohammad Faranoush, MD, Oluyemi Fasina, FWACS, Delia D.P.G. Fernández, MSc, Ana Fernández-Teijeiro, MD, PhD, Allen Foster, FRCOphth, Shahar Frenkel, MD, PhD, Ligia D. Fu, MD, Soad L. Fuentes-Alabi, MD, MPH, Juan L. Garcia, MSc, David García Aldana, MD, Henry N. Garcia Pacheco, MD, Jennifer A. Geel, MBChB, MMed, Fariba Ghassemi, MD, Ana V. Girón, MD, Marco A. Goenz, MD, Aaron S. Gold, OD, Hila Golberg, MD, Glen A. Gole, MD, FRANZCO, Nir Gomel, MD, Efren Gonzalez, MD, Graciela Gonzalez Perez, MD, Liudmira González-Rodríguez, MD, Malka Gorfine, PhD, Jaime Graells, MD, Pernille A. Gregersen, MD, Nathalia D.A.K. Grigorovski, MD, Koffi M. Guedenon, MD, D Sanjeeva Gunasekera, MD, Ahmet K. Gündüz, MD, Himika Gupta, MD, Sanjiv Gupta, MS, Vineeta Gupta, MD, Theodora Hadjistilianou, MD, Patrick Hamel, MD, Syed A. Hamid, FCPS, Norhafizah Hamzah, MSc, Eric D. Hansen, MD, J William Harbour, MD, M. Elizabeth Hartnett, MD, Murat Hasanreisoglu, MD, Sadiq Hassan, MD, FWACS, Shadab Hassan, FRCS, FCPS, Wojciech Hautz, MD, Huda A. Haydar, CHD, Stanislava Hederova, MD, Laila Hessissen, MD, Hoby Lalaina, MD, Suradej Hongeng, MD, Diriba F. Hordofa, MD, G. Baker Hubbard, MD, Marlies Hummlen, MD, Kristina Husakova, MD, Allawi N. Hussein Al-Janabi, MD, Affiong A. Ibanga, MB.BCh, FMCOph, Russo Ida, MD, Vesna R. Ilic, MD, Ziyavuddin Islamov, MD, Vivekaraj Jairaj, DNB, Teyyeb A. Janjua, MD, FCPS, FRCSEd, Irfan Jeeva, FRCOphth, Xunda Ji, MD, Dong Hyun Jo, MD, PhD, Michael M. Jones, MD, PhD, FRANZCO, Theophile B. Amani Kabesha, MD, PhD, Rolande L. Kabore, MD, Abubakar Kalinaki, MD, Pius Kamsang, MD, Mehmet Kantar, MD, Noa Kapelushnik, MD, Tamar Kardava, PhD, Rejin Kebudi, MD, Jonny Keomisy, MD, Tomas Kepak, MD, Petra Ketteler, MD, Zohora J. Khan, MD, Hussain A. Khaqan, MD, Vikas Khetan, FRCS, FACS, Alireza Khodabande, MD, Zaza Khotenashvili, MD, Jonathan W. Kim, MD, Jeong Hun Kim, MD, PhD, Hayyam Kiratli, MD, Tero T. Kivelä, MD, Artur Klett, MD, PhD, Irem Koç, MD, Jess Elio Kosh Komba Palet, MD, Dalia Krivaitiene, MD, PhD, Mariana Kruger, Mmed Paed, PhD, Kittisak Kulvichit, MD, Mayasari W. Kuntorini, MD, Alice Kyara, BA, Geoffrey C. Lam, FRANZCO, Scott A. Larson, MD, Slobodanka Latinović, MD, PhD, Kelly D. Laurenti, MD, Yotam Lavi, MD, PhD, Alenka Lavric Groznik, MD, Amy A. Leverant, MD, Cairui Li, MD, Kaijun Li, MD, Ben Limbu, MD, Chun-Hsiu Liu, MD, Quah Boon Long, FRCS (Ed), MMed ( Ophth), FAMS, Juan P. López, MD, Robert M. Lukamba, MD, Sandra Luna-Fineman, MD, Delfitri Lutfi, MD, Lesia Lysytsia, MD, Shiran Madgar, MD, George N. Magrath, MD, Amita Mahajan, MD, Puja Maitra, MD, Erika Maka, MD, Emil K. Makimbetov, MD, Azza M.Y. Maktabi, MD, Carlos Maldonado, MD, Ashwin Mallipatna, MD, Rebecca Manudhane, MD, Lyazat Manzhuova, MD, Nieves Martín Begue, MD, PhD, Sidra Masud, MBBS, Ibrahim O. Matende, MD, M. Med (Oph), Clarissa C.D.S. Mattosinho, MD, Marchelo Matua, BAPH, Ismail Mayet, MD, Freddy B. Mbumba, MD, MMed Paed, John D. McKenzie, MD, Azim Mehrvar, MD, Aemero A. Mengesha, MD, Vikas Menon, MD, Gary John V.D.D. Mercado, MD, Marilyn B. Mets, MD, Edoardo Midena, MD, PhD, Audra Miller, MD, Divyansh K.C. Mishra, DNB, Furahini G. Mndeme, MD, Ahmed A. Mohamedani, FRCPath, Mona T. Mohammad, MD, FRCS, Annette C. Moll, MD, PhD, Margarita M. Montero, MD, Claude Moreira, MD, PhD, Prithvi Mruthyunjaya, MD, MHS, Mchikirwa S. Msina, MMed Ophth, Gerald Msukwa, MMed Ophth, Sangeeta S. Mudaliar, DNB Pediatric, Hassan Muhammad, MD, Kangwa I. Muma, MMed Ophth, FCOphth, Francis L. Munier, MD, Timothy G. Murray, MD, MBA, Kareem O. Musa, FWACS, FMCOphth, FICO, Asma Mushtaq, MD, Anne A. Musika, MD, Hamzah Mustak, MD, Tajudeen Mustapha, MBBS, FWACS, Okwen M. Muyen, MD, Khumo H. Myezo, Msc, Gita Naidu, MMed Paed, PhD, Natasha Naidu, MBCHB, FCS Ophthalmol, Akshay Gopinathan Nair, MD, Sundaram Natarajan, FRCS, Larisa Naumenko, MD, PhD, Paule Aïda Ndoye Roth, MD PhD, Yetty M. Nency, MD, Vladimir Neroev, MD, PhD, Yvonne Ng, MBChB ( Auckland) , FRANZCO, Marina Nikitovic, MD, PhD, Elizabeth D. Nkanga, FMCOph, Henry E. Nkumbe, MD, Marcel N. Numbi, MD, Kalle Nummi, MD, Murtuza Nuruddin, FRCS, Mutale Nyaywa, MD, MMed Ophth, FCOphth, Chinsisi Nyirenda, MD, Ghislaine Obono-Obiang, MD, Scott C.N. Oliver, MD, Joaquin Ooporto, MD, Miriam Ortega-Hernández, MD, Alexander Oscar, MD, Diego Ossandon, MD, Halimah Pagarra, MD, PhD, Vivian Paintsil, FWACP, Luisa Paiva, MD, Mahesh Shanmugam Palanivelu, FRCSED, Ruzanna Papyan, MD, Raffaele Parrozzani, MD, PhD, Claudia R. Pascual Morales, MD, Katherine E. Paton, MD, FRCSC, Jacob Pe'er, MD, Jesús Peralta Calvo, MD, Sanja Perić, MD, PhD, Chau T.M. Pham, MD, Remezo Philbert, MD, David A. Plager, MD, Pavel Pochop, MD, PhD, Rodrigo A. Polania, MD, Vladimir Polyakov, MD, Jimena Ponce, MD, Ali O. Qadir, MD, Seema Qayyum, FCPS, Jiang Qian, MD, Ardizal Rahman, MD, Purnima Rajkarnikar, MD, Rajesh Ramanjulu, MD, Aparna Ramasubramanian, MD, Marco A. Ramirez-Ortiz, MD, MPH, Jasmeen K. Randhawa, BA, Léa Raobela, MD, Riffat Rashid, MS, M. Ashwin Reddy, FRCOphth, Lorna A. Renner, FRCPCH (UK), David Reynders, MD, Dahiru Ribadu, FMCOph, Petra Ritter-Sovinz, MD, Anna Rogowska, MD, Duangnate Rojanaporn, MD, Livia Romero, MD, Soma R. Roy, DCO, Raya H. Saab, MD, Svetlana Saakyan, MD, PhD, Ahmed H. Sabhan, MD, Mandeep S. Sagoo, FRCS (Ed), Azza M.A. Said, MD, Rohit Saiju, MD, Beatriz Salas, MD, Sonsoles San Román Pacheco, MD, Gissela L. Sánchez, MD, Alma Janeth Sanchez Orozco, MD, Phayvanh Sayalith, MD, Trish A. Scanlan, MRCPI, MSc, Christoph Schwab, MD, Ahad Sedaghat, MD, Rachna Seth, DNB MNAMS, Mariana Sgroi, MD, Ankoor S. Shah, MD, PhD, Shawkat A. Shakoor, MS, Manoj K. Sharma, MD, Sadik T. Sherief, MD, Carol L. Shields, MD, David Sia, MB ChB, FRANZCO, Sorath Noorani Siddiqui, MD, Sidi Sidi cheikh, MD, PhD, Sónia Silva, MD, Arun D. Singh, MD, Usha Singh, MS, Penny Singha, MD, Rita S. Sitorus, MD, PhD, Alison H. Skalet, MD, PhD, Hendrian D. Soebagjo, MD, PhD, Tetyana Sorochynska, MD, PhD, Grace Ssali, MD, Andrew W. Stacey, MD, Sandra E. Staffieri, PhD, Erin D. Stahl, MD, David M. Steinberg, PhD, David K. Stones, MBChB, FCPaed, Caron Strahlendorf, MD, Maria Estela Coleoni Suarez, MD, Sadia Sultana, FCPS, Xiantao Sun, MD, Rosanne Superstein, MD, Eddy Supriyadi, MD, PhD, Supawan Surukrattanaskul, MD, Shigenobu Suzuki, MD, PhD, Karel Svojgr, MD, PhD, Fatoumata Sylla, MD, Gevorg Tamamyan, MD, PhD, Deborah Tan, MBBS, Alketa Tandili, MD, PhD, Jing Tang, MD, Fanny F. Tarrillo Leiva, MD, Maryam Tashvighi, MD, Bekim Tateshi, MD, PhD, Kok Hoi Teh, MD, Edi S. Tehuteru, MD, Luiz F. Teixeira, MD, Manca Tekavcic Pompe, MD, PhD, Abdullah Dahan M. Thawaba, MD, Tuyisabe Theophile, MSc, Helen Toledano, MBChB, Doan L. Trang, MD, Fousseyni Traoré, MD, Devjyoti Tripathy, MD, Samuray Tuncer, MD, Harba Tyau-Tyau, MD, Ali B. Umar, MD, FMCPath, Emel Unal, MD, Ogul E. Uner, BA, Steen F. Urbak, MD, PhD, Tatiana L. Ushakova, MD, Rustam H. Usmanov, MD, Sandra Valeina, MD, Paola Valente, MD, Milo van Hoefen Wijsard, MD, Jacqueline Karina Vasquez Anchaya, MD, Leon O. Vaughan, FRCS (Ed), Nevyana V. Veleva-Krasteva, MD, PhD, Nishant Verma, MD, Andi A. Victor, MD, PhD, Maris Viksnins, MD, Edwin G. Villacís Chafla, MD, Victor M. Villegas, MD, Victoria Vishnevskia-Dai, MD, Keith Waddell, DM, FRCP, FRCS, FRCOphth, Amina H. Wali, MD, FMCOph Nigeria, Yi-Zhuo Wang, MD, Nutsuchar Wangtiraumnuay, MD, FICO, Julie A. Wetter, MMed Rad Onc, FCRad Onc, Widiarti P. Riono, MD, Matthew W. Wilson, MD, Amelia D.C. Wime, MD, Atchareeya Wiwatwongwana, MD, Damrong Wiwatwongwana, MD, Charlotte Wolley Dod, MD, Emily S. Wong, FCOphth HK, FHKAM, Phanthipha Wongwai, MD, PhD, Si-qi Wu, MSc, Daoman Xiang, MD, PhD, Yishuang Xiao, MSc, Bing Xu, MD, Kang Xue, MD, Antonio Yaghy, MD, Jason C. Yam, FRCSEd, Huasheng Yang, MD, Jenny M. Yanga, MD, Muhammad A. Yaqub, MD, FCPS, FRCSEd, Vera A. Yarovaya, MD, Andrey A. Yarovoy, MD, PhD, Huijing Ye, MD, Roberto I. Yee, MD, Yacoub A. Yousef, MD, Putu Yuliawati, MD, Arturo M. López, MD, Ekhtelbenina Zein, MD, Yi Zhang, MD, PhD, Katsiaryna Zhilyaeva, MD, Nida Zia, MBBS, MCPS, Othman A.O. Ziko, MD, PhD, Marcia Zondervan, MBA, Sabrina Schlüter, MD, and Richard Bowman, FRCOphth

Subjects
External beam radiotherapy, Extraocular extension, Multimodal treatment, Retinoblastoma, Tumor, Ophthalmology, RE1-994
Abstract

Purpose: To study the treatment and outcomes of children with retinoblastoma (RB) with extraocular tumor extension (RB-EOE) and compare them with RB without extraocular tumor extension (RB-w/o-EOE). Design: Multicenter intercontinental collaborative prospective study from 2017 to 2020. RB-EOE cases included those with overt orbital tumor extension in treatment-naive patients. Cases with microscopic orbital extension detected postenucleation were excluded from the study. Participants: A total of 319 children with RB-EOE and 3116 children with RB-w/o-EOE. Intervention: Chemotherapy, enucleation, exenteration, radiotherapy. Main Outcome Measures: Systemic metastasis and death. Results: Of the 3435 RB patients included in this study, 309 (9%) were from low-income countries (LIC), 1448 (42%) from lower-middle income, 1012 (29%) from upper-middle income, and 666 (19%) patients from high-income countries. There was an inverse relationship between the percentage of RB-EOE and national income level, with 96 (31%) patients from LIC, 197 (6%) lower-middle income, 20 (2%) upper-middle income, and 6 (1%) patients from high-income countries (P = 0.0001). The outcomes were statistically significant for RB-EOE compared with RB-w/o-EOE: systemic metastasis (32% vs. 4% respectively; P = 0.0001) and metastasis-related death (63% vs. 6% respectively; P = 0.0001). Multimodal treatment was the most common form of treatment (n = 177; 54%) for RB-EOE, with most cases undergoing a combination of intravenous chemotherapy and enucleation (n = 97; 30%). Adjuvant external beam radiotherapy (EBRT) after surgery (enucleation/orbital exenteration) was given in only 68 (21%) cases. Kaplan–Meier analysis for systemic metastasis and metastasis-related death in RB-EOE was 28% and 57% at 1 year, 29% and 60% at 2 years, and 29% and 61% at 3 years, respectively. Cox regression analysis revealed that the risk of death from RB-EOE was greater in patients aged >4 years than

Published
2025
Full Text
View/download PDF

2. Anti-proliferative and anti-tumour effects of lymphocyte-derived microparticles are neither species- nor tumour-type specific

Author

Chun Yang, Wei Xiong, Qian Qiu, Houda Tahiri, Rosanne Superstein, Anne-Sophie Carret, Przemyslaw Sapieha, and Pierre Hardy

Subjects
microparticles, lymphocytes, tumour growth, anti-proliferation, cell cycle, Cytology, QH573-671
Abstract

Background: Unregulated cell proliferation or growth is a prominent characteristic of cancer. We have previously demonstrated that LMPs (cell membrane microparticles derived from apoptotic human CEM T lymphoma cells stimulated with actinomycin D) strongly suppress the proliferation of not only human endothelial cells but also mouse Lewis lung carcinoma cells. Methods: LMPs were generated either from CEM T cells using different stimuli or from 3 different types of lymphocytes. The effects of LMPs on cancer cell proliferation were examined using cell lines from different species and tissues. The cell cycle kinetics was evaluated by FACS and the expression of cell cycle-related genes was determined using quantitative RT-PCR. The in vivo anti-tumor effect of LMPs was investigated using xenografts and allografts. Results: LMPs at doses far above physiological levels dramatically suppressed the proliferation of cancer cells in a non species-specific manner. LMPs selectively target high proliferating cells and their anti-proliferative effect is not dependent on parental cell origin or stimuli. The anti-proliferative effect of LMPs was due to induction of cell-cycle arrest in G0/G1, with associated increases in expression of the cyclin-dependent kinase inhibitors p15INK4b, p16INK4a, and p21Cip1. In vivo, LMPs significantly suppressed tumor growth in animal tumor models. Conclusion: These results highlight the potential role of LMPs in modulating the growth of high proliferating cells. Given that cell-based therapies are considered less toxic than pharmacologic approaches and have the potential to target multiple pathways in a synergistic manner, LMPs may serve as a veritable option for cancer treatment.

Published
2014
Full Text
View/download PDF

3. Three‐year observation of children 12 to 35 months old with untreated intermittent exotropia

Author

Jonathan M. Holmes, Raymond T. Kraker, B. Michele Melia, Danielle L. Chandler, Eric R. Crouch, Brian G. Mohney, Evelyn A. Paysse, Rosanne Superstein, Susan A. Cotter, David K. Wallace, and Rui Wu

Subjects
Male, Pediatrics, medicine.medical_specialty, Time Factors, medicine.medical_treatment, Visual Acuity, Article, Occlusion, medicine, Humans, Strabismus, Vision, Binocular, business.industry, Clinical course, Infant, medicine.disease, Sensory Systems, Confidence interval, Ophthalmology, Child, Preschool, Chronic Disease, Disease Progression, Exotropia, Female, business, Motor deterioration, Intermittent exotropia, Watchful waiting, Follow-Up Studies, Optometry
Abstract

PURPOSE: To describe the clinical course of untreated intermittent exotropia (IXT) in children 12 to 35 months of age followed for three years. METHODS: We enrolled 97 children 12 to 35 months of age with previously untreated IXT who had been randomly assigned to the observation arm of a randomised trial of short-term occlusion versus observation. Participants were observed unless deterioration criteria were met at a follow-up visit occurring at 3 months, 6 months, and 6-month intervals thereafter for three years. The primary outcome was deterioration of the IXT by three years, defined as (1) a constant exotropia ≥10 prism dioptres (∆) at distance and near (i.e., motor deterioration) or (2) treatment prescribed despite not having met motor deterioration. The primary analysis used the Kaplan-Meier method to determine the cumulative proportion of participants meeting deterioration by three years and 95% confidence interval (CI). RESULTS: The cumulative probability of deterioration by three years was 28% (95% CI = 20% to 39%). Of the 24 participants meeting the primary outcome of deterioration, seven met motor deterioration and 17 were prescribed treatment without meeting motor deterioration. The cumulative probability of motor deterioration by three years was 10% (95% CI = 5% to 19%). CONCLUSIONS: Given the modest rate of motor deterioration over three years, watchful waiting may be a reasonable management approach in 12- to 35-month-old children with IXT. To confirm this recommendation would require a long-term randomised trial of immediate treatment versus observation followed by deferred treatment if needed.

Published
2020
Full Text
View/download PDF

4. Co-delivery of miR-181a and melphalan by lipid nanoparticles for treatment of seeded retinoblastoma

Author

Rabeb Mouna Derbali, Pierre Hardy, Chun Yang, Patrick Hamel, Seyed Nasrollah Tabatabaei, Jeanne Leblond Chain, Rosanne Superstein, Université de Montréal (UdeM), and Université de Montréal [Montréal]

Subjects
Melphalan, Male, [SDV.BIO]Life Sciences [q-bio]/Biotechnology, Retinal Neoplasms, Cell, Pharmaceutical Science, Apoptosis, 02 engineering and technology, Rats, Sprague-Dawley, 03 medical and health sciences, [SDV.SP.MED]Life Sciences [q-bio]/Pharmaceutical sciences/Medication, Cell Line, Tumor, microRNA, medicine, Cytotoxic T cell, Animals, Humans, [CHIM]Chemical Sciences, Antineoplastic Agents, Alkylating, 030304 developmental biology, Cell Proliferation, 0303 health sciences, Liposome, Retinoblastoma, Chemistry, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, 021001 nanoscience & nanotechnology, medicine.disease, Lipids, Xenograft Model Antitumor Assays, 3. Good health, Rats, Gene Expression Regulation, Neoplastic, MicroRNAs, medicine.anatomical_structure, [SDV.SP.PG]Life Sciences [q-bio]/Pharmaceutical sciences/Galenic pharmacology, Cell culture, Cancer research, Nanoparticles, 0210 nano-technology, medicine.drug
Abstract

International audience; Melphalan is an efficient chemotherapeutic agent that is currently used to treat retinoblastoma (Rb); however, the inherent risk of immunogenicity and the hazardous integration of this drug in healthy cells is inevitable. MicroRNAs are short non-coding single-stranded RNAs that affect a vast range of biological processes. Previously, we focused on the regulatory role of miR-181a during cancer development and progression. In this manuscript, 171 nm switchable lipid nanoparticles (LNP) co-delivered melphalan and miR-181a with en-capsulation efficiencies of 93%. Encapsulation of melphalan in LNP significantly improved its therapeutic efficiency. Gene analysis shows that miR-181a decreases the expression of anti-proliferative gene MAPK1 and anti-apoptotic gene Bcl-2, but significantly increased the expression of pro-apoptotic gene BAX. Our results suggest that the two agents have a complementary effect in reducing the viability of cultured Rb cells (primary and cell line) and decreasing Rb cell counts in an in-vivo xenograft Rb model in rats. Our results suggest that the proposed co-delivery technique significantly increases the therapeutic impact, allows for lower administration of melphalan, and consequently, could minimize the cytotoxic side-effects of this drug.

Published
2019
Full Text
View/download PDF

5. Tonic pupil after botulinum toxin-A injection for treatment of esotropia in children

Author

Rosanne Superstein, David K. Wallace, Raymond T. Kraker, Katherine A. Lee, Alejandra G. de Alba Campomanes, Stephen P. Christiansen, Julie Morin, Danielle L. Chandler, and Erick D. Bothun

Subjects
Male, medicine.medical_specialty, Adolescent, genetic structures, Pilot Projects, Tonic Pupil, Injections, Intramuscular, Article, Botulinum toxin a, 03 medical and health sciences, 0302 clinical medicine, Humans, Medicine, Botulinum Toxins, Type A, Child, Strabismus, Anisocoria, Esotropia, Tonic pupil, business.industry, Infant, Mean age, medicine.disease, eye diseases, Surgery, Ophthalmology, Left eye, Neuromuscular Agents, Oculomotor Muscles, Child, Preschool, Anesthesia, Pediatrics, Perinatology and Child Health, 030221 ophthalmology & optometry, Female, medicine.symptom, Complication, business, 030217 neurology & neurosurgery
Abstract

A total of 27 children with esotropia (mean age, 3.9 years; range, 9 months to 13.8 years) were enrolled in a 9-month observational study following botulinum toxin A (BTX-A) injection of one (n = 7) or both (n = 20) medial rectus muscles. BTX-A dosage ranged from 3.0 to 6.0 units per muscle. Three participants developed tonic pupil, noted at the first follow-up visit, occurring 12-19 days after injection. All 3 cases occurred in the left eye of participants who underwent bilateral BTX-A injection by the same surgeon. Anisocoria diminished from a maximum of 4 mm at the 2-week visit to 1–2 mm in all patients over the 9-month postinjection data collection period. No adverse visual outcomes were noted. Tonic pupil is an infrequently reported complication of BTX-A injection for strabismus. The experience of our investigator group suggests the need for careful injection technique and thorough preinjection counseling.

Published
2016
Full Text
View/download PDF

6. A Randomized Clinical Trial Of Immediate versus Delayed Spectacles for Moderate Hyperopia in 1- and 2-Year-Olds

Author

John M. Avallone, Donny W. Suh, David B. Petersen, S. Ayse Erzurum, Alex Christoff, Trevano W. Dean, Raymond T. Kraker, Marjean Taylor Kulp, Jonathan M. Holmes, Ruth E. Manny, Tawna L Roberts, Rosanne Superstein, David K. Wallace, Susan A. Cotter, David A. Leske, and Deborah R. Fishman

Subjects
Male, Pediatrics, medicine.medical_specialty, genetic structures, Visual Acuity, Article, law.invention, Anisometropia, Time-to-Treatment, 03 medical and health sciences, 0302 clinical medicine, Randomized controlled trial, law, medicine, Humans, Vision test, Prospective Studies, Strabismus, Dioptre, 030304 developmental biology, 0303 health sciences, Depth Perception, business.industry, Vision Tests, Astigmatism, Infant, medicine.disease, Confidence interval, eye diseases, Stereoscopic acuity, Ophthalmology, Eyeglasses, Hyperopia, Prescriptions, Child, Preschool, 030221 ophthalmology & optometry, Patient Compliance, Female, business, Strabismus surgery, Follow-Up Studies
Abstract

OBJECTIVE: Two strategies were compared for managing moderate hyperopia without manifest strabismus among 1- and 2-year-old children: 1) immediate prescription of glasses vs 2) observation without glasses unless reduced distance visual acuity (VA), reduced stereoacuity, or manifest strabismus. DESIGN: Prospective randomized clinical trial PARTICIPANTS: 130 children 1 to 2 years old with hyperopia between +3.00 diopters (D) and +6.00D spherical equivalent (SE) in at least one eye, anisometropia ≤1.50D SE and astigmatism ≤1.50D based on cycloplegic refraction, and no manifest strabismus. METHODS: Participants were randomly assigned to glasses (1.00D less than full cycloplegic hyperopia) versus observation and followed every 6 months for 3 years. Glasses were prescribed to those assigned to observation if they met pre-specified deterioration criteria of distance VA or near stereoacuity below age norms, or development of manifest strabismus. MAIN OUTCOME MEASURE: At the 3-year primary outcome examination, participants were classified as failing the randomized management regimen if distance VA or stereoacuity were below age norms, or manifest strabismus was observed (each with and without correction in trial frames, confirmed by masked retest, irrespective of whether deterioration had occurred previously), or if strabismus surgery had been performed. RESULTS: Of the 106 (82%) participants completing the 3-year primary outcome examination, failure occurred in 11 (21%) of 53 in the glasses group and 18 (34%) of 53 in the observation group (difference = −13%; 95% CI = −31% to 4%; p=0.14). The reasons for failure in the glasses and observation groups were reduced stereoacuity in 6 (11%) and 16 (30%) respectively, reduced VA in 3 (6%) and 4 (8%), and manifest strabismus in 5 (9%) in each group. Fifty-eight percent (95% CI = 46% to 70%) in the observation group, and 33% (95% CI = 22% to 46%) in the glasses group met deterioration criteria (requiring glasses if not wearing). CONCLUSION: For 1- and 2-year-olds with uncorrected moderate hyperopia (+3.00D to +6.00D SE), our estimates of failure, after 3 years of 6-monthly follow-up, are inconclusive, and consistent with either a small to moderate benefit or no benefit of immediate prescription of glasses compared with careful observation (with glasses only if deteriorated).

Published
2019

7. Relationship among clinical factors in childhood intermittent exotropia

Author

Rosanne Superstein, Jonathan M. Holmes, Raymond T. Kraker, David K. Wallace, B. Michele Melia, R. Grey Weaver, Eileen E. Birch, Danielle L. Chandler, Sean P. Donahue, Susan A. Cotter, Brian G. Mohney, and Trevano W. Dean

Subjects
Male, medicine.medical_specialty, Visual acuity, Distance exotropia, Visual Acuity, Fixation, Ocular, Near exotropia, Article, Anisometropia, 03 medical and health sciences, 0302 clinical medicine, Ophthalmology, medicine, Humans, 030212 general & internal medicine, Child, Analysis of Variance, Depth Perception, business.industry, medicine.disease, Stereoscopic acuity, Child, Preschool, Pediatrics, Perinatology and Child Health, 030221 ophthalmology & optometry, Optometry, Exotropia, Minimum deviation, Female, medicine.symptom, business, Intermittent exotropia
Abstract

To determine the relationships between stereoacuity, control of exotropia, and angle of deviation in children with intermittent exotropia (IXT).Data collected for 652 participants 3 to11 years of age with IXT meeting eligibility criteria for enrollment into one of two multicenter, randomized clinical trials were used to evaluate relationships between stereoacuity, control, and angle of deviation at enrollment.Any level of stereoacuity and angle of deviation could be accompanied by any level of control. Worse distance exotropia control was weakly associated with poorer distance stereoacuity (R = 0.26; 99% CI, 0.17-0.36) and larger angles of deviation at distance (R = 0.27; 99% CI, 0.17-0.36). Worse near exotropia control was weakly associated with poorer near stereoacuity (R = 0.17; 99% CI, 0.07-0.27) and moderately associated with larger angles of deviation at near (R = 0.37; 99% CI, 0.28-0.45). There was no association between stereoacuity and angle of deviation at distance (R = 0.07; 99% CI, -0.03 to 0.17) or at near (R = 0.02; 99% CI, -0.08 to 0.12).Although weak and moderate associations were found between stereoacuity, control, and angle of deviation, a child may exhibit any combination of stereoacuity, control, and angle of deviation. The specific roles of control, stereoacuity, and angle of deviation in the diagnosis, management, and pathogenesis of IXT are unclear, and each appears to yield somewhat independent information.

Published
2017

8. Multiple Cranial Nerve Palsies in Giant Cell Arteritis

Author

Lulu L. C. D. Bursztyn, Rosanne Superstein, Mark Gans, and Michael G. Ross

Subjects
Male, Pathology, medicine.medical_specialty, Retinal Artery Occlusion, Eye Movements, Ocular motor, Biopsy, Giant Cell Arteritis, 03 medical and health sciences, 0302 clinical medicine, Ocular Motility Disorders, Medicine, Humans, Aged, Aged, 80 and over, medicine.diagnostic_test, business.industry, Ischemic optic neuropathy, medicine.disease, Cranial Nerve Diseases, Temporal Arteries, Ophthalmology, Giant cell arteritis, Oculomotor Muscles, 030221 ophthalmology & optometry, Neurology (clinical), Complication, business, 030217 neurology & neurosurgery, Systemic vasculitis
Abstract

Giant cell arteritis (GCA) is a systemic vasculitis of medium and large arteries often with ophthalmic involvement, including ischemic optic neuropathy, retinal artery occlusion, and ocular motor cranial nerve palsies. This last complication occurs in 2%-15% of patients, but typically involves only 1 cranial nerve. We present 2 patients with biopsy-proven GCA associated with multiple cranial nerve palsies.

Published
2017

10. 81: Neurodevelopmental Outcomes of Extremely Preterm Infants Treated with Bevacizumab for Severe Retinopathy of Prematurity

Author

Marie-Noëlle Simard, Francine Lefebvre, Thuy Mai Luu, E Kelly, Julie Morin, V Shah, Prachi E. Shah, and Rosanne Superstein

Subjects
Pediatrics, medicine.medical_specialty, Bevacizumab, business.industry, Objective (goal), Birth weight, Extremely preterm, Retinopathy of prematurity, medicine.disease, Bayley Scales of Infant Development, Laser therapy, Pediatrics, Perinatology and Child Health, Medicine, business, medicine.drug
Published
2015
Full Text
View/download PDF

11. Evaluation of the Intermittent Exotropia Questionnaire Using Rasch Analysis

Author

Daniel J. Karr, Michelle Bass, Rebecca Dent, Richard London, Laura B. Enyedi, Annette Bade, Wanda Pfeifer, Aaron M. Miller, Matthew D. Gearinger, B. Michele Melia, Monica Pacheco, Susan A. Cotter, Heather A Anderson, Heather Klem, Kenneth Adams, Joan Roberts, Donny W. Suh, Tammy Price, Sergul Erzurum, Ruth E. Manny, Ronald G.W. Teed, Peter Macdowell, Elise Harb, Melanie Christian, Reena Patel, Ann U. Stout, Troy Kieser, Raymond H. Chu, Anesu Mvududu, Vivian Wong, Tawna L Roberts, Angela Chen, Tamara S Oechslin, Richard L. Weaver, Michele Whitaker, Paula Rauch, Nancy Stevens, Elias I. Traboulsi, Karen Pollack, Noelle S. Matta, Robert P. Rutstein, Cheryl Capobianco, Paul G. Steinkuller, Gaylord Ventura, Carol Bradham, Mei Mellott, Darren L. Hoover, Jacqueline Rodena, Heidi Martin, Brian J. Forbes, Jill S. Anderson, Mary Louise Z. Collins, Robert Peters, Gil Binenbaum, Stephen P. Christiansen, Jayne Silver, Phoebe D. Lenhart, Marcela Frazier, Yasmin S. Bradfield, Kimberly G. Yen, Sara Meeder, Eileen Dittman, Lisa Fraine, Emi Sanders, Don Lyon, Nandini G. Gandhi, Wendy Marsh-Tootle, Pamela A. Huston, Ilana B Friedman, Lori Cooke, Beth Colon, Jonathan M. Holmes, Shelley Klein, Rosanne Superstein, Susannah Q. Longmuir, Sarah R. Hatt, Joan Do, Carmen Barnhardt, William F. Astle, Daniel E. Neely, Robert Duckman, Benjamin H. Ticho, Dipali Dave, Susanna M. Tamkins, Vanessa Vazquez, Rebecca Nielsen, Marilyn Vricella, Lernik Mesropian, Robert L. Estes, Gregory Ostrow, Laura Kirkeby, David G. Morrison, Andrew J. Toole, Nicole Fallaha, Paul J. Rychwalski, Kristy Dunlap, Susan Parker, Jeanine Romeo, David K. Wallace, Aaliyah Hamidullah, Edward Cheeseman, Mitchell Scheiman, David A. Leske, Caroline Belanger, Diana McOwen, Brian W. Arthur, Hee Jung Park, David I. Silbert, Tammy L. Yanovitch, David B. Petersen, Alex Christoff, Lesley Macsween, Sean P. Donahue, Xiaonong Liu, Eric Hein, David Robbins Tien, Lori Ann F. Kehler, Evelyn Koestenblatt, Indre M. Rudaitis, Jan Hilbrands, Sarah K. Jones, C. Gail Summers, Catherine Heyman, Jennifer Brady, Maynard Wheeler, Katherine K. Weise, Jorie Jackson, Ann M. Holleschau, Allison I. Summers, Kenneth Romanchuk, Megan Allen, Christie L. Morse, Inge De Becker, Sarah Downes, Tomohiko Yamada, Mitchell B. Strominger, Brian G. Mohney, David K. Coats, Susan Hayes, Freda Dallas, Amy K. Hutchinson, Deborah Clausius, Maryse Thibeault, Stacy L. Pineles, Lingkun Kong, Airaj Fasiuddin, Jeffery Colburn, Paula Handford, Blair Spencer, Tamiesha Frempong, Mae Millicent W. Peterseim, Hawke Yoon, Angela Alfaro, Catherine McDaniel, Jean E. Ramsey, Laura Liebermann, Laura Graham, Karen A. Karp, Stephen Van Iderstine, Earl R. Crouch, Evelyn A. Paysse, Alexander Khammar, Patricia L. Davis, J. McMurtrey, Bahram Rahmani, Judy Brower, Todd Goldblum, Yana Kiesau, Stephen R. Glaser, Scott R. Lambert, Karen D. Fern, Tara Cronin, Justin Smith, Maureen Flanagan, Marjean Taylor Kulp, Susan Crowe, Allison Jensen, Michael X. Repka, Adriana P. Grigorian, Nausheen Khuddus, Michael Bartiss, Ross Roegner, Faruk Ogre, Erick D. Bothun, Kristine Huang, Erin Herlihy, Daniel M. Laby, Mary A O'Hara, Tennille McGaw, Nicholas A. Sala, Samantha Garner, Mohamed A.W. Hussein, Barbara Soderling, Marianne Esguerra, and Yi Pang

Subjects
Male, medicine.medical_specialty, Adolescent, Cross-sectional study, Health Status, Article, Proxy (climate), Sickness Impact Profile, Surveys and Questionnaires, Humans, Medicine, Child, Rasch model, business.industry, Infant, Reproducibility of Results, medicine.disease, Ophthalmology, Cross-Sectional Studies, Child, Preschool, Cohort, Quality of Life, Physical therapy, Exotropia, Female, business, Intermittent exotropia, Psychosocial, Cohort study
Abstract

Importance The Intermittent Exotropia Questionnaire (IXTQ) is a patient, proxy, and parental report of quality of life specific to children with intermittent exotropia. We refine the IXTQ using Rasch analysis to improve reliability and validity. Observation Rasch analysis was performed on responses of 575 patients with intermittent exotropia enrolled from May 15, 2008, through July 24, 2013, and their parents from each of the 4 IXTQ health-related quality-of-life questionnaires (child 5 through 7 years of age and child 8 through 17 years of age, proxy, and parent questionnaires). Questionnaire performance and structure were confirmed in a separate cohort of 379 patients with intermittent exotropia. One item was removed from the 12-item child and proxy questionnaires, and response options in the 8- to 17-year-old child IXTQ and proxy IXTQ were combined into 3 response options for both questionnaires. Targeting was relatively poor for the child and proxy questionnaires. For the parent questionnaire, 3 subscales (psychosocial, function, and surgery) were evident. One item was removed from the psychosocial subscale. Resulting subscales had appropriate targeting. Conclusions and Relevance The Rasch-revised IXTQ may be a useful instrument for determining how intermittent exotropia affects health-related quality of life of children with intermittent exotropia and their parents, particularly for cohort studies.

Published
2015
Full Text
View/download PDF

12. Diverses modalités de traitement des troubles d’apprentissage scolaire par thérapies visuelles: quelles sont les évidences scientifiques?

Author

Isabelle Denault, Rosanne Superstein, Nicole Fallaha, and Amélie Ganivet

Subjects
General Medicine
Abstract

Les troubles d’apprentissage sont des désordres complexes qui entravent le développement normal des processus d’acquisition et de traitement de l’information. ils sont couramment rencontrés au sein de la population pédiatrique et peuvent se manifester sous diverses formes dont la plus fréquente est la dyslexie. Les troubles d’apprentissage ont une nature chronique et n’ont pas pour cause première des handicaps visuels, auditifs et/ ou moteurs, la déficience intellectuelle, la perturbation affective ni même un milieu défavorisé. Cependant, il est possible que ces troubles puissent coexister avec l’un ou l’autre de ces problèmes. Puisque les enfants qui en sont atteints rencontrent souvent des difficultés de taille lors des apprentissages fondamentaux dès leur entrée à l’école primaire, il est essentiel de leur offrir un soutien adapté, un diagnostic précoce et une intervention efficace. Plusieurs hypothèses impliquant divers problèmes visuels ont été émises quant à la cause de la dyslexie et des troubles d’apprentissage. La présente revue de littérature traite de ces diverses hypothèses de traitement des troubles d’apprentissage scolaire par thérapies visuelles. L’analyse démontre qu’il n’y a pas de preuves scientifiques suffisantes à ce jour prouvant que la thérapie visuelle, les lunettes d’entraînement, les exercices de poursuites et de saccades, les exercices perceptuels, les lunettes grossissantes, les filtres ou lentilles colorées ainsi que les prismes peuvent améliorer significativement les troubles d’apprentissage.

Published
2014
Full Text
View/download PDF

13. Real-time Ophthalmoscopic Findings of Intraophthalmic Artery Chemotherapy in Retinoblastoma

Author

Anne Sophie Carret, Josée Dubois, Patrick Hamel, Rosanne Superstein, S.A. Callejo, and Nicole Fallaha

Subjects
medicine.medical_specialty, Chemotherapy, medicine.diagnostic_test, business.industry, Retinoblastoma, medicine.medical_treatment, medicine.disease, Chemotherapy regimen, Ophthalmoscopy, Ophthalmology, medicine.anatomical_structure, Medicine, Radiology, business, Artery
Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results